Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

The commenter supports the FDA's proposed information collection on human drug compounding to improve patient safety and regulatory oversight. They suggest that the FDA should focus on refining data collection methods to reduce administrative burdens and leverage standardized electronic reporting.